Home › Funds › Soleus Capital Management, L.P. › XENE

Soleus Capital Management, L.P. position in XENE

XENON PHARMACEUTICALS INC · Health Care

Soleus Capital Management, L.P. reported holding 267,000 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$16.1M, representing 0.56% of its reported portfolio and ranking #46 among its reported holdings. Soleus Capital Management, L.P. has disclosed XENE holdings in 5 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)267.00K sh
Reported value held$16.12M
Portfolio Weight0.56%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s XENE position evolved

Soleus Capital Management, L.P. first disclosed a stake in XENE in Q3 2023 at 52,000 shares (US$1.8M). The position peaked in Q1 2026 at 292,000 shares, worth US$17.0M. Across 5 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 267,000 shares valued at US$16.1M — a reduction of -25,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 52.00K $1.78M New
Q4 2023 58.00K $2.67M Add
Q2 2025 78.80K $2.47M New
Q1 2026 292.00K $16.98M New
Q2 2026 267.00K $16.12M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Soleus Capital Management, L.P. held XENE?

Soleus Capital Management, L.P. has disclosed XENE holdings in 5 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in XENE?

As of Q2 2026, Soleus Capital Management, L.P. holds 267.00K shares of XENE (XENON PHARMACEUTICALS INC), valued at $16.12M, representing 0.56% of its reported portfolio and ranking #46.

Has Soleus Capital Management, L.P. been buying or selling XENE?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in XENE. The position peaked in Q1 2026 at 292.00K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.